AIDS: PATHOGENESIS AND TREATMENT NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


AIDS: PATHOGENESIS AND TREATMENT

Immunol Ser; 44:1-632 1989. Unique Identifier : AIDSLINE ICDB/90656683
Anonymous; No affiliation given

Abstract: The extent of the spread of AIDS and the degree of its pathogenicity match those of the great epidemics of the past. The virulence is due to several unique attributes of the AIDS agent, the human immunodeficiency virus. It is spread by intimate contact, affording little exposure to neutralizing antibodies. As a retrovirus, it is genetically highly variable in antigenicity because it lacks the remediation intrinsic to DNA replication. It integrates into the host cell genome, perhaps for the life of the host. It seems to circumvent an effective cytotoxic T-cell response. Among its major targets are the cell populations responsible for initiating and maintaining an immune response--the macrophage and helper/inducer lymphocyte. Review of the epidemiology, pathogenesis, and treatment of AIDS includes the following topics: AIDS in Africa and in Haiti; AIDS and hemophilia and in transfusion recipients; pediatric AIDS; heterosexual transmission of HIV; the HIVs (detection and pathogenesis); the molecular biology of HIV infection, including clues for possible therapy; immunologic effects of HIV infection; pathology of AIDS; the persistent lymphadenopathy syndrome and immune thrombocytopenic purpura in HIV-infected individuals; Kaposi's sarcoma, lymphomas, and other neoplasms associated with AIDS; CNS disorders in AIDS; pulmonary complications of AIDS; hairy leukoplakia and other oral features of HIV infection; other infections associated with AIDS; other virus infections associated with AIDS (cytomegalo-, herpes simplex, Epstein-Barr, and hepatitis B viruses); developing comprehensive care systems for individuals with HIV infection; and the pursuit of an AIDS virus vaccine.
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Antiviral Agents/*THERAPEUTIC USE Human HIV/IMMUNOLOGY Immunotherapy/*METHODS MONOGRAPHKWDacquiredimmunodeficiencysyndrome/immunology/KWDtherapyantiviralagents/KWDtherapeuticusehumanhiv/immunologyimmunotherapy/KWDmethodsmonograph
900228
M9020588

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .